Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - Defendants allegedly made unauthorized design changes to the G6 and G7 systems that compromised their reliability and safety [2]. - The enhancements claimed for the G7 device were reportedly overstated, leading to potential health risks for users relying on these devices for accurate glucose readings [2]. - DexCom is accused of downplaying the severity of issues related to the G7 devices, which could result in increased regulatory scrutiny and significant legal and financial repercussions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the enhancements to the G7 device were overstated, and the true scope of issues related to the G7 devices was downplayed by the defendants [5]. - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [5].

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations of the Lawsuit - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The complaint asserts that the enhancements to the G7 and its reliability, accuracy, and functionality were overstated by the defendants [2] - Defendants allegedly downplayed the severity of the issues and health risks associated with the altered G7 devices [2] - The lawsuit indicates that these actions exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2] - As a result, the public statements made by the defendants were claimed to be materially false and misleading [2] Group 2: Next Steps for Affected Investors - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information via the provided link or contact the firm directly for further details [3][6]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including a notable recovery of over $438 million for investors in 2019 [4]. - Investors are advised that until a class is certified, they are not represented unless they retain counsel, and they have the option to remain absent from the class [7].

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DexCom, Inc. (NASDAQ:DXCM) and Wildermuth Fund (NASDAQ:WEFCX, NASDAQ:WESFX. NASDAQ:WEIFX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. DexCom, Inc. (NASDAQ:DXCM) Class Period: ...

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability [2]. - The design changes reportedly posed a material health risk to users who relied on these devices for accurate glucose readings [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, while downplaying the severity of issues related to adulterated devices [2]. - The company faces increased regulatory scrutiny and potential legal, reputational, and financial harm due to these allegations [2]. Group 2: Legal Process for Investors - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and selects counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].

NEW YORK, Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=179561&from=4CLASS PERIOD: January 8, 2024 to Septembe ...

Core Insights - DexCom, Inc. has launched Dexcom Academy, a personalized learning platform for healthcare professionals (HCPs) focused on continuous glucose monitoring (CGM) [1][2] - The platform aims to enhance HCP confidence in CGM use and improve diabetes care quality without increasing clinical burden [2][4] Group 1: Platform Features - Dexcom Academy offers both desktop and mobile app access, allowing HCPs to select learning resources that fit their needs through short, flexible modules [2][6] - The platform includes structured learning pathways, practical case studies, and certification courses to support professional development [6][7] - Educational resources are designed to be consultation-ready, enabling HCPs to apply their learning immediately in patient interactions [6][7] Group 2: HCP Feedback and Needs - Dexcom collaborated with HCPs to create a platform that addresses their needs for flexible, personalized, and practical education [3][5] - A survey indicated that 38% of HCPs believe ongoing education on diabetes technology is essential for overcoming challenges in patient care [4][9] - HCPs expressed a desire for training that is relevant and based on real case studies, which Dexcom Academy aims to provide [5][6] Group 3: Future Plans and Commitment - Dexcom plans to expand the availability of Dexcom Academy to more EMEA countries by 2026, demonstrating a long-term commitment to supporting diabetes care [1][8] - The initiative reflects Dexcom's investment in both product excellence and the education necessary for effective diabetes management [8][10]

Core Viewpoint - A securities fraud class action lawsuit has been filed against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its Dexcom G7 continuous glucose monitoring system, impacting investors who purchased shares between January 8, 2024, and September 17, 2025 [4][5]. Group 1 - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who acquired DexCom securities during the specified period [4]. - Allegations include that the company and certain senior officers made false statements about the device's reliability and enhancements, as well as the expansion of manufacturing capabilities [5]. - Investors interested in participating as lead plaintiffs must file by December 26, 2025, although participation in any recovery does not require serving as lead plaintiff [6]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [7].

Core Viewpoint - DexCom, Inc. is a leading medical device company specializing in continuous glucose monitoring systems, with a market cap of $24.8 billion, indicating its significant influence in the diabetes care market [1][2]. Company Overview - DexCom designs and commercializes CGM systems, including a small implantable device for measuring glucose levels and an external receiver for data transmission [1]. - The company is categorized as a large-cap stock, reflecting its substantial market presence and dominance in the medical devices industry [2]. Market Performance - DexCom's stock has experienced a decline of 30.9% from its 52-week high of $93.25, reached on February 18, and has underperformed the S&P 500 Index, which gained 6.5% over the same period [3]. - Over the past six months, DexCom shares fell by 24.6%, and over the past year, they decreased by 18.7%, significantly lagging behind the S&P 500's gains of 15.1% and 12.9%, respectively [4]. Technical Analysis - The stock has been trading below its 200-day moving average since early August, indicating a bearish trend, although it recently traded above the 50-day moving average [4]. Challenges and Concerns - The company's underperformance is attributed to an FDA warning letter regarding manufacturing issues, trade war concerns with China affecting supply chains, and higher scrap rates along with sensor deployment issues [5]. - Management is optimistic about improvements due to new quality controls and shipping methods [5]. Financial Results - In Q3, DexCom reported an adjusted EPS of $0.61, exceeding Wall Street's expectation of $0.57, and revenue of $1.21 billion, surpassing the forecast of $1.18 billion [6]. - The company anticipates full-year revenue between $4.6 billion and $4.7 billion [6].